

Doctor's Order Sheet

**pembrolizumab 2 mg/kg -  
Abraxane® (nab-PACLitaxel)  
260 - CISplatin 50 - Zirabev® (bevacizumab)**

**15 mg/kg Regimen (Part I) Cycle 7 +**

**ARIA Protocol Name:** pembrolizumab2 Abraxane260 CISplatin50 bevacizumab15

Adult Chemotherapy - Gynecologic Oncology

Persistent, Recurrent or Metastatic Cervical Cancer Treatment



CC7210 0541 03 2025

Name: \_\_\_\_\_

HCN: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

**Allergies:**

**No Known**

Date: DD/MONTH/YYYY

Planned Administration Date: DD/MONTH/YYYY

Cycle      of     

**Cycle Duration: 21 days**

Date of previous cycle: DD/MONTH/YYYY

**MAY PROCEED WITH DOSES AS WRITTEN IF:**

- ANC **greater than or equal to** 1.0 X 10<sup>9</sup>/L and platelets **greater than or equal to** 100 X 10<sup>9</sup>/L, otherwise notify Gynecologic Oncologist.
- LFT's and Bilirubin assessed.
- Creatinine clearance assessed.
- Dipstick urine or laboratory urinalysis for protein assessed.
- Thyroid function assessed.

**PREMEDICATIONS (FOR HOSPITAL PHARMACY):**

Other: \_\_\_\_\_

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Doctor's Order Sheet  
**pembrolizumab 2 mg/kg -  
Abraxane® (nab-PACLitaxel)  
260 - CISplatin 50 - Zirabev®**

Name: \_\_\_\_\_

HCN: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

**(bevacizumab) 15 mg/kg Regimen (Part II) Cycles 7 +**

**ARIA Protocol Name: pembrolizumab2 Abraxane260 CISplatin50 bevacizumab15**

Adult Chemotherapy - Gynecologic Oncology

Persistent, Recurrent or Metastatic Cervical Cancer Treatment



CC7210 0541 03 2025

Weight: \_\_\_\_\_ kg      Height: \_\_\_\_\_ cm      Body Surface Area (BSA) = \_\_\_\_\_

**CHEMOTHERAPY (FOR HOSPITAL PHARMACY):**

**pembrolizumab 2 mg/kg X Weight (kg) = \_\_\_\_\_ mg (maximum dose 200mg)**

**IV** in 50 mL normal saline over 30 minutes on day 1

**Zirabev® (bevacizumab) 15 mg/kg X Weight (kg) = \_\_\_\_\_ mg**

Dose modification: **Zirabev® (bevacizumab) 15 mg/kg X weight (kg) - \_\_\_\_\_ % = \_\_\_\_\_ mg**

**IV** in 100 to 250 mL normal saline on day 1 over:

— **60** minutes during **Cycle 1**;

— If tolerated without reaction - **30** minutes during **Cycle 2** and all other cycles

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.